Welcome to the Medical Faculty of the University of Bonn

The powerhouse of the cells – known as mitochondria – appear to be able to influence the number of lipid droplets in the cell. A mechanism that is actually intended for a completely different purpose plays a central role in this. This is shown by a recent study by the University of Bonn and University Hospital Bonn and the University of Freiburg. The results have now been published in the journal Nature Cell Biology.

The Epstein-Barr virus (EBV) can cause certain types of cancer or autoimmune diseases, but how the body controls this common viral infection is largely unknown. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now identified genetic and non-genetic factors that help the body fight EBV. To do this, they evaluated genome sequencing data, which is actually intended for characterizing the human genome, in a new way. Using the new technique, they were able to estimate the amount of EBV in the blood and find correlations in large health data sets – for example, an increased viral load in people with HIV infections, but also in smokers. There were also indications of new genes that play key roles in EBV immunity. Their findings have now been published in the renowned journal Nature.

The University of Bonn is acknowledging the International Day of Women and Girls in Science on February 11 by reaffirming its aim of promoting gender equality in academia. Women are still significantly underrepresented in many research fields at university level, and the trend is more marked the higher up the career ladder one goes. The University has launched numerous initiatives and programs to tackle the problem.

A groundbreaking approach that targets the degradation of membrane proteins in cancer cells has received funding from the European Innovation Council (EIC) Pathfinder program. The goal: To target previously "undruggable" cancer-related proteins by selectively degrading them and potentially offering a new way to overcome resistance to current cancer therapies.